Torrent Pharmaceuticals Ltd.'s consolidated net profit rose 14% in the third quarter of the current financial year, in line with analysts' estimates.
The company posted a net profit of Rs 503 crore in the quarter ended Dec. 31, 2024, in comparison to Rs 443 crore in the year-ago period, according to an exchange filing on Friday. Analysts tracked by Bloomberg had estimated a profit of Rs 514 crore.
Torrent Q3 FY25 Earnings Highlights (Consolidated, YoY)
Revenue up 2.8% to Rs 2809 crore versus Rs 2732 crore (Bloomberg estimate: Rs 3,003 crore).
Ebitda up 5.2% to Rs 914 crore versus Rs 869 crore (Estimate: Rs 976 crore).
Margin at 32.5% versus 31.8% (Estimate:32.5 %).
Net profit up 13.5% to Rs 503 crore versus Rs 443 crore (Estimate: Rs 514 crore).
Shares of Torrent Pharmaceuticals closed 0.46% lower at Rs 3248.9 apiece on the NSE, compared to a 0.49% decline in the benchmark Nifty 50.
RECOMMENDED FOR YOU

Cybersecurity Watchdog Issues Advisory After Exposure of 1,600 Crore Online Credentials


Torrent Expects JB Pharma Deal To Reach Completion Over 15-18 Months


Nazara Technologies Gets ICICI Securities 'Add' Downgrade; Sees Limited Upside At Current Valuations


Torrent Pharma – JB Chemicals Acquisition: What Should JB Chemicals Shareholders Do?
